Traditional Herbal Supplement Registration in Thailand: Food or Traditional Medicine?

A herbal product entering the Thai market has to answer one question before anything else: is it a food supplement, or is it a traditional medicine product? Thailand runs two entirely separate regulatory pathways for traditional and herbal products, and each carries its own registration requirements, permitted claims, and level of regulatory oversight. Getting the pathway wrong does not just create a paperwork headache; it reshapes the marketing strategy, the GMP standard the manufacturer has to meet, and the claims the brand can legally make in Thailand.

Two pathways, two different regulatory worlds

The food supplement pathway runs under the Notification of the Ministry of Public Health on Food Supplements (No. 293) and suits herbal products positioned around nutritional support, general wellness, or non-therapeutic health maintenance. Products here register with Thai FDA's Food Division under the same food safety standards that apply to any other supplement, and they cannot make traditional medicine claims or imply treatment of a disease condition.

The traditional medicine pathway runs under the Herbal Product Act B.E. 2562 (2019) and covers Thai Traditional Medicine, Traditional Chinese Medicine, and herbal products carrying traditional use claims. These register with Thai FDA's Traditional Medicine and Herbal Products Division and can draw on traditional pharmacopeial evidence and historical use, within the limits the Act specifies. GMP requirements for manufacturing sit on a separate, distinct standard from the food supplement track.

What actually decides which pathway applies

The pathway determination for a herbal product comes down to three factors working together: the ingredient list, the intended claims, and the dosage form. A product built entirely from herbal ingredients can still qualify as a food supplement if its claims avoid traditional medicine language and its formulation is not drawn primarily from combinations traditionally used in Thai or Chinese medicine for treating specific conditions.

Ingredients designated as Thai traditional medicine herbs in the Thai Traditional Medicine Pharmacopoeia, or formulations drawn from the National List of Essential Traditional Medicines, push firmly toward the traditional medicine pathway. A product built from Western botanicals with no TTMP or TCM pharmacopeial status, marketed without traditional medicine framing, can reasonably use the food supplement route instead.

Claims matter just as much as ingredients. Any language calling a product "traditional medicine," "Thai herbal remedy," or referencing a traditional therapeutic indication, "used in Thai traditional medicine for fever," for instance, or "a TCM formulation for liver qi stagnation," triggers the traditional medicine pathway regardless of what's actually in the formula. Brands wanting the food supplement route need to avoid that framing entirely and stick to generic wellness language.

Dosage form can decide the question on its own, independent of claims or ingredients. Traditional forms strongly associated with traditional medicine practice, herbal balls (luk glorn in TTM) or traditional decoction concentrates, are treated as traditional medicine products no matter how the marketing is worded. Standard supplement formats, capsules, tablets, softgels, sachets, do not by themselves trigger the traditional medicine pathway.

Botanical ingredients inside the food supplement pathway

Herbal products taking the food supplement route still have to meet the same food safety standards as any other supplement ingredient. Botanicals with a recognized history of safe food use in Thailand, common culinary herbs and spices, and botanicals traditionally consumed as food or drink, clear without novel food assessment. Botanicals new to the Thai food supply, or used historically only in a traditional medicine context with no separate food-use history, need novel food assessment before they can go into a food-pathway product. Ashwagandha (Withania somnifera) is a frequently cited example: it has no traditional Thai food-use history and typically requires novel food review, as do a number of Ayurvedic botanicals with strong international evidence bases but no history in Thai food.

Regardless of novelty status, every botanical ingredient in a food supplement dossier needs identification data (scientific name, plant part, preparation method), quality specifications covering identity tests, heavy metal limits, and pesticide residue data, and stability data confirming that marker compound content, where applicable, holds through the claimed shelf life under Zone IVb tropical storage conditions.

Inside the traditional medicine pathway

Products under the Herbal Product Act fall into three groups: Thai Traditional Medicine products using TTMP formulations, Traditional Chinese Medicine products using Chinese Pharmacopoeia or Thai FDA TCM reference formulations, and herbal products that fit neither TTM nor TCM but carry traditional use claims backed by documented evidence. The dossier itself looks different from a food supplement file: evidence rests on traditional use documentation and pharmacopeial monographs rather than the clinical safety and efficacy data pharmaceuticals require, and Thai FDA's Traditional Medicine Division evaluates that evidence within the Thai traditional medicine framework rather than against Western clinical trial standards.

Manufacturing has its own separate GMP standard here too, the Thai GMP for Traditional Medicine Products, distinct from both the food supplement GMP standard and pharmaceutical GMP. Foreign manufacturers exporting traditional medicine products into Thailand need to demonstrate compliance with this standard or an equivalent recognized one, though the equivalence pathway for traditional medicine is considerably less developed than it is for pharmaceuticals.

Deciding before you build the dossier

Pathway choice for a herbal product is not a purely regulatory decision. It shapes the marketing strategy, the distribution channels open to the product, and the advertising claims permitted in Thailand, and those commercial implications need weighing before committing to one route over the other. DeeMED Consulting advises on this pathway determination before any registration work begins, and where botanicals are involved, we run the novel food status assessment early enough to flag whether additional safety data is needed and how long generating it will take. If you're bringing a herbal product into Thailand and the pathway isn't obvious yet, our dietary supplement registration work is the right place to start that determination.

The cost of choosing the wrong pathway after launch

Brands occasionally discover the pathway question only after a product is already registered and selling, usually when marketing wants to refresh the positioning with language that turns out to trigger reclassification. A food supplement brand that adds "traditional Thai remedy" language to a new marketing campaign, without checking that phrase against the pathway triggers first, can find itself facing a Thai FDA inquiry into whether the product's registration still matches its actual market presentation. Reversing that kind of exposure after the fact, pulling marketing materials, potentially re-registering under the traditional medicine pathway with a different evidence package, and explaining the gap to Thai FDA, costs far more in time and legal exposure than getting the pathway determination right at the outset would have.

This risk runs in both directions. A product correctly registered under the traditional medicine pathway that later wants to expand into mainstream wellness retail, where the traditional medicine framing may limit which distribution channels will carry it, faces the same kind of strategic tension from the other side. Retailers positioning themselves around general wellness sometimes prefer products without traditional medicine registration status, seeing it as narrowing the target consumer, which means the pathway decision made at registration can quietly shape which retail partnerships are realistically available years later. Treating the food-versus-traditional-medicine choice as a one-time regulatory filing decision, rather than a strategic one with downstream commercial consequences, is the mistake that costs brands the most time to unwind.